Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution
Authors
Keywords
-
Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 112, Issue 11, Pages 3320-3325
Publisher
Proceedings of the National Academy of Sciences
Online
2015-03-03
DOI
10.1073/pnas.1416159112
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Intratumoral Immunization: A New Paradigm for Cancer Therapy
- (2014) A. Marabelle et al. CLINICAL CANCER RESEARCH
- Crucial Role of Aspartic Acid at Position 265 in the CH2 Domain for Murine IgG2a and IgG2b Fc-Associated Effector Functions
- (2014) L. Baudino et al. JOURNAL OF IMMUNOLOGY
- IL-2: The First Effective Immunotherapy for Human Cancer
- (2014) S. A. Rosenberg JOURNAL OF IMMUNOLOGY
- High efficiency cell-specific targeting of cytokine activity
- (2014) Geneviève Garcin et al. Nature Communications
- The Dose-Dependent Tumor Targeting of Antibody-IFN Fusion Proteins Reveals an Unexpected Receptor-Trapping Mechanism In Vivo
- (2014) T. Hemmerle et al. Cancer Immunology Research
- Peripherally Administered Nanoparticles Target Monocytic Myeloid Cells, Secondary Lymphoid Organs and Tumors in Mice
- (2013) Iraklis C. Kourtis et al. PLoS One
- A new platform for constructing antibody-cytokine fusion proteins (immunocytokines) with improved biological properties and adaptable cytokine activity
- (2013) S. D. Gillies PROTEIN ENGINEERING DESIGN & SELECTION
- Optimization of Multivalent Bispecific Antibodies and Immunocytokines with Improved in Vivo Properties
- (2012) Edmund A. Rossi et al. BIOCONJUGATE CHEMISTRY
- Role of Chemokines and Chemokine Receptors in Shaping the Effector Phase of the Antitumor Immune Response
- (2012) K. Franciszkiewicz et al. CANCER RESEARCH
- Immunocytokines: a novel class of potent armed antibodies
- (2012) Nadine Pasche et al. DRUG DISCOVERY TODAY
- Intratumoral hu14.18-IL-2 (IC) Induces Local and Systemic Antitumor Effects That Involve Both Activated T and NK Cells As Well As Enhanced IC Retention
- (2012) R. K. Yang et al. JOURNAL OF IMMUNOLOGY
- Tumor penetration and epidermal growth factor receptor saturation by panitumumab correlate with antitumor activity in a preclinical model of human cancer
- (2012) Daniel J Freeman et al. Molecular Cancer
- A Low-Toxicity IL-2-Based Immunocytokine Retains Antitumor Activity Despite Its High Degree of IL-2 Receptor Selectivity
- (2011) S. D. Gillies et al. CLINICAL CANCER RESEARCH
- Mouse Phenome Database (MPD)
- (2011) Terry P. Maddatu et al. NUCLEIC ACIDS RESEARCH
- Antitumor Activity of Hu14.18-IL2 in Patients With Relapsed/Refractory Neuroblastoma: A Children's Oncology Group (COG) Phase II Study
- (2010) Suzanne Shusterman et al. JOURNAL OF CLINICAL ONCOLOGY
- Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma
- (2010) Alice L. Yu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2
- (2008) C. Schliemann et al. BLOOD
- Intratumoral immunocytokine treatment results in enhanced antitumor effects
- (2008) Erik E. Johnson et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now